WO2007060911A1 - アロエベラ抽出物、アロエベラ抽出物の製造方法、高血糖改善剤 - Google Patents
アロエベラ抽出物、アロエベラ抽出物の製造方法、高血糖改善剤 Download PDFInfo
- Publication number
- WO2007060911A1 WO2007060911A1 PCT/JP2006/323095 JP2006323095W WO2007060911A1 WO 2007060911 A1 WO2007060911 A1 WO 2007060911A1 JP 2006323095 W JP2006323095 W JP 2006323095W WO 2007060911 A1 WO2007060911 A1 WO 2007060911A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- aloe vera
- oral
- vera extract
- mass
- Prior art date
Links
- 235000014104 aloe vera supplement Nutrition 0.000 title claims abstract description 88
- 238000000034 method Methods 0.000 title claims abstract description 45
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 21
- 201000001421 hyperglycemia Diseases 0.000 title claims description 46
- 230000008569 process Effects 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 81
- -1 anthraquinone compound Chemical class 0.000 claims abstract description 48
- 235000013305 food Nutrition 0.000 claims abstract description 47
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 238000000194 supercritical-fluid extraction Methods 0.000 claims abstract description 24
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 235000011399 aloe vera Nutrition 0.000 claims description 49
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 42
- 238000000605 extraction Methods 0.000 claims description 31
- 150000002989 phenols Chemical class 0.000 claims description 27
- 239000000284 extract Substances 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 13
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 9
- AOQRDALGACAKHI-KVCRWQBISA-N (9r,10s,13r,14r,17r)-17-[(2r,5s)-5,6-dimethylheptan-2-yl]-4,10,13-trimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound CC1C(O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@H](C)C(C)C)CC[C@H]33)C)C3=CCC21 AOQRDALGACAKHI-KVCRWQBISA-N 0.000 claims description 8
- KKSCKZFKHNHGEO-UHFFFAOYSA-N 24-methylenecycloartanol Natural products CC(CCC(=C)C(C)(C)O)C1CCC2C3CCC4C(C)(C)C(O)CCC45CC35CCC12C KKSCKZFKHNHGEO-UHFFFAOYSA-N 0.000 claims description 8
- AOQRDALGACAKHI-UHFFFAOYSA-N 4-methylergost-7-en-3-ol Natural products CC1C(O)CCC2(C)C(CCC3(C(C(C)CCC(C)C(C)C)CCC33)C)C3=CCC21 AOQRDALGACAKHI-UHFFFAOYSA-N 0.000 claims description 8
- RRTBTJPVUGMUNR-UHFFFAOYSA-N Cycloartanol Natural products C12CCC(C(C(O)CC3)(C)C)C3C2(CC)CCC2(C)C1(C)CCC2C(C)CCCC(C)C RRTBTJPVUGMUNR-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- IYIFZADLIMVECH-QYQNSBOUSA-N (9r,10s,13r,14r,17r)-17-[(2r,5r)-5-ethyl-6-methylheptan-2-yl]-4,10,13-trimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound CC1C(O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CCC21 IYIFZADLIMVECH-QYQNSBOUSA-N 0.000 claims description 6
- IYIFZADLIMVECH-UHFFFAOYSA-N 4-methylstigmast-7-en-3-ol Natural products CC1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CCC21 IYIFZADLIMVECH-UHFFFAOYSA-N 0.000 claims description 6
- LMYZQUNLYGJIHI-SPONXPENSA-N 4alpha-methyl-5alpha-cholest-7-en-3beta-ol Chemical compound C[C@@H]1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 LMYZQUNLYGJIHI-SPONXPENSA-N 0.000 claims description 6
- LMYZQUNLYGJIHI-UHFFFAOYSA-N Methostenol Natural products CC1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CCC21 LMYZQUNLYGJIHI-UHFFFAOYSA-N 0.000 claims description 6
- 239000001569 carbon dioxide Substances 0.000 claims description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 6
- 244000186892 Aloe vera Species 0.000 claims 3
- 239000000864 hyperglycemic agent Substances 0.000 claims 1
- 150000004056 anthraquinones Chemical class 0.000 abstract description 14
- 201000010099 disease Diseases 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 239000000463 material Substances 0.000 abstract description 8
- 230000002265 prevention Effects 0.000 abstract description 3
- 238000011109 contamination Methods 0.000 abstract description 2
- 244000144927 Aloe barbadensis Species 0.000 description 39
- 210000004369 blood Anatomy 0.000 description 36
- 239000008280 blood Substances 0.000 description 36
- 230000000694 effects Effects 0.000 description 30
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 29
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 24
- 239000008103 glucose Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 21
- 239000003814 drug Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 15
- 206010012601 diabetes mellitus Diseases 0.000 description 14
- 239000000499 gel Substances 0.000 description 14
- 235000002378 plant sterols Nutrition 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 102000001554 Hemoglobins Human genes 0.000 description 11
- 108010054147 Hemoglobins Proteins 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 241001116389 Aloe Species 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000003345 hyperglycaemic effect Effects 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 229930182558 Sterol Natural products 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000003702 sterols Nutrition 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 238000000638 solvent extraction Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- BSLYZLYLUUIFGZ-JRUDBKCSSA-N 4,4,14-trimethyl-9,19-cyclo-5alpha,9beta-cholestane Chemical compound C1CCC(C)(C)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@@]3(C)[C@@H]1CC2 BSLYZLYLUUIFGZ-JRUDBKCSSA-N 0.000 description 3
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- KFJNVVJUICKJEQ-LQDZTQBFSA-N aloenin Chemical compound O1C(=O)C=C(OC)C=C1C1=C(C)C=C(O)C=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 KFJNVVJUICKJEQ-LQDZTQBFSA-N 0.000 description 3
- KFJNVVJUICKJEQ-UHFFFAOYSA-N aloenin Natural products O1C(=O)C=C(OC)C=C1C1=C(C)C=C(O)C=C1OC1C(O)C(O)C(O)C(CO)O1 KFJNVVJUICKJEQ-UHFFFAOYSA-N 0.000 description 3
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 3
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 3
- 235000000431 campesterol Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- XZEUYTKSAYNYPK-UHFFFAOYSA-N 3beta-29-Norcycloart-24-en-3-ol Natural products C1CC2(C)C(C(CCC=C(C)C)C)CCC2(C)C2CCC3C(C)C(O)CCC33C21C3 XZEUYTKSAYNYPK-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 240000007474 Aloe arborescens Species 0.000 description 2
- 235000004509 Aloe arborescens Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 206010012665 Diabetic gangrene Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- HVXLSFNCWWWDPA-UHFFFAOYSA-N Isocycloartenol Natural products C1CC(O)C(C)(C)C2C31CC13CCC3(C)C(C(CCCC(C)=C)C)CCC3(C)C1CC2 HVXLSFNCWWWDPA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- HXQRIQXPGMPSRW-UHZRDUGNSA-N Pollinastanol Natural products O[C@@H]1C[C@H]2[C@@]3([C@]4([C@H]([C@@]5(C)[C@@](C)([C@H]([C@H](CCCC(C)C)C)CC5)CC4)CC2)C3)CC1 HXQRIQXPGMPSRW-UHZRDUGNSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- ONQRKEUAIJMULO-YBXTVTTCSA-N cycloartenol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@@]3(C)[C@@H]1CC2 ONQRKEUAIJMULO-YBXTVTTCSA-N 0.000 description 2
- YNBJLDSWFGUFRT-UHFFFAOYSA-N cycloartenol Natural products CC(CCC=C(C)C)C1CCC2(C)C1(C)CCC34CC35CCC(O)C(C)(C)C5CCC24C YNBJLDSWFGUFRT-UHFFFAOYSA-N 0.000 description 2
- FODTZLFLDFKIQH-UHFFFAOYSA-N cycloartenol trans-ferulate Natural products C1=C(O)C(OC)=CC(C=CC(=O)OC2C(C3CCC4C5(C)CCC(C5(C)CCC54CC53CC2)C(C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-UHFFFAOYSA-N 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000009160 phytotherapy Methods 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229950005143 sitosterol Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 150000003432 sterols Chemical class 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- HPJKMKFYRFNYKI-KMBWXDHGSA-N (9R,10S,13R,14R,17R)-17-[(2R,5R)-5-ethyl-6-methylheptan-2-yl]-4,10,13-trimethyl-2,3,4,5,6,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene Chemical compound CC1C2CC=C3[C@@H]4CC[C@H]([C@@H](CC[C@@H](CC)C(C)C)C)[C@]4(CC[C@@H]3[C@]2(CCC1)C)C HPJKMKFYRFNYKI-KMBWXDHGSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- VFYFMNCKPJDAPV-UHFFFAOYSA-N 2,2'-(5-oxo-1,3-dioxolan-4,4-diyl)diessigs Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CC1(CC(O)=O)OCOC1=O VFYFMNCKPJDAPV-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- BDHQMRXFDYJGII-UEBIAWITSA-N 24-methylenecycloartanol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@H](C)CCC(=C)C(C)C)CC[C@@]3(C)[C@@H]1CC2 BDHQMRXFDYJGII-UEBIAWITSA-N 0.000 description 1
- BJZVHTWNCLKZGN-SPQNPFHSSA-N 24-methylidenecycloartanol Natural products CC(C)C(=C)CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C(C)(C)[C@@H](O)CC[C@@]45C[C@@]35CC[C@]12C BJZVHTWNCLKZGN-SPQNPFHSSA-N 0.000 description 1
- LYTVDXWBHQIFHO-GMZLGSTCSA-N 4-[[(3s,8s,9s,10r,13r,14s,17r)-17-[(e,2r,5s)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4-oxobutanoic acid Chemical compound C1C=C2C[C@@H](OC(=O)CCC(O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 LYTVDXWBHQIFHO-GMZLGSTCSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 241000499316 Asphodelaceae Species 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 1
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000011012 sanitization Methods 0.000 description 1
- 210000002107 sheath cell Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0203—Solvent extraction of solids with a supercritical fluid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- Aloe vera extract production method of aloe vera extract, hyperglycemia improving agent
- the present invention relates to an aloe vera extract in which the content of a mixture comprising a cyclolanostane compound and an oral phenol compound is 1.0% by mass or more, and the aloe vera extract using a supercritical extraction method And an antihyperglycemic agent comprising an aloe vera extract having an active ingredient content of 1.0% by mass or more as a mixture of cyclolanostanic compound and oral phenolic compound.
- a hyperglycemic state is a state in which the blood glucose level is outside the normal region, which is a fasting blood glucose level of lOmgZdl or less, a blood glucose level of 160mgZdl in 1 hour after 75g sugar load, and 2 hours
- the blood glucose level is defined as 120 mgZdl in this state (Non-patent Document 1).
- Hemoglobin Ale is a combination of glucose and hemoglobin that increases with the degree of hyperglycemia, and once produced hemoglobin Ale does not disappear until the red blood cell life (120 days) is exhausted. It is regarded as an indicator of long-term blood glucose control status (Non-patent Document 1).
- Plant sterols are broadly classified into three groups: 4 desmethyl sterols, 4 monomethyl sterols, and 4, 4 dimethyl sterols, and 4 desmethyl sterols are generally widely known. Cholesterol, campesterol, brush castellonoles, sitostero nore, stigmastellonole, fucostello nore, etc. 4-monomethinosterol includes oral phenol, horiool, , Cycloalanol, lupeol, etc. are known respectively.
- the technology for isolating plant sterols using the supercritical extraction method includes one-stage and two-stage supercritical fluid extraction techniques for carotene concentrate, vitamin E concentrate, and other trace component concentrates. It is disclosed.
- a method for producing plant sterols contained in konjac koji using a supercritical extraction method Patent Document 6
- a method for extracting plant sterols campesterol, stigmasterol, ⁇ -sitosterol contained in natural fats and oils
- a blood cholesterol-lowering agent, a prostatic hypertrophy ameliorating agent, a food and drink Patent Document 7 and the like containing the same are disclosed.
- the genus Aloe is a kind of succulent plant including Aloe barbadenisis Miller and Aloe arbo rescen Miller var. Natalensis Berger, and has been empirically known to have various effects. Yes. Among the effects of these aloe plants, blood sugar level improvement Prior art on effects includes clinical trials in the United States (Non-patent Document 2), blood glucose-lowering effects in animals (Non-Patent Document 3 or 4), and blood sugar levels of polysaccharides in Aloe plants The action (Patent Document 8) is disclosed. Furthermore, an aloe vera pressing solution and a blood glucose level lowering agent comprising the pressing solution as an active ingredient (Patent Document 9) are disclosed.
- the following techniques are disclosed as techniques for extracting active ingredients in aloe that exhibit an effect of improving blood glucose level.
- a method for producing an aloe vera gel stock solution consisting of sterilization and disinfection with chlorine, 90-degree superheating and filtration (Patent Document 10), and a method for producing an aloe vera gel compressed solution characterized by performing all steps at 75 ° C or lower ( (Patent Document 11), Aloe Vera squeezed solution (Patent Document 12), which was heated at 60 ° C for 30 minutes and treated with activated carbon, silicon earth and sanitizing filter after the squeezing and filtering process.
- Patent Document 15 a technique for recovering the ethanol-soluble portion of the supernatant obtained by ultracentrifugation of aloe vera, partitioning and extracting the fraction with butanol, and producing an extract with an effect of improving immunosuppression (patent Reference 14) and a technique for producing an anti-obesity improving agent by distributing and extracting an aqueous solution of an aloe-pressed solution or a solvent extract with ethyl acetate or butanol (Patent Document 15) are disclosed.
- Patent Document 1 Japanese Patent Application Laid-Open No. 2003-95941
- Patent Literature 3 Special Table 2002-542161
- Patent Document 4 Japanese Patent Laid-Open No. 57-018617
- Patent Document 5 JP2003--277269
- Patent Document 6 Japanese Unexamined Patent Publication No. 2005- — 87998
- Patent Document 8 JP-A-60-214741
- Patent Document 9 JP 2003-286185 A Patent Document 10: Japanese Patent Application Laid-Open No. 2002-68997
- Patent Document 11 Japanese Patent Laid-Open No. 2002-284661
- Patent Document 12 Japanese Unexamined Patent Application Publication No. 2002-205955
- Patent Document 13 Japanese Patent No. 2832551
- Patent Document 14 JP-A-8-208495
- Patent Document 15 Japanese Unexamined Patent Publication No. 2000-319190
- Non-Patent Document 1 Japanese Clinical, Volume 808, 2nd, 405-409, 2002
- Non-patent 2 Phytomedicine, 3rd, 245-248, 1996
- Non-Patent Document 3 Phytotherapy Research, 15th, 157-161, 2001
- Non-Patent Document 4 Phytotherapy Research, 7th, 37-42, 1993
- aloe vera gel aloe vera mesophyll
- water a solid part
- most of the solid part is composed of polysaccharides, making it a food form that can be used for physical problems.
- the content of ineffective ingredients in aloe vera gel must be taken into account.
- Patent Document 6 or 7 discloses a method for extracting plant sterols by supercritical extraction, plant sterols having an effect of improving hyperglycemia are efficiently recovered, and anthraquinones are obtained. A method for obtaining an extract free of There was no mention or suggestion at all.
- the present inventors have conducted intensive studies with the aim of obtaining a form (composition) suitable for adding aloe vera as a functional food material that is sufficiently active and can be added to food. Piled up.
- cyclolano has a composition almost reflecting the mixing ratio of plant sterols contained in natural aloe vera.
- the present invention has been completed by finding the characteristics of an extract containing a Stanley compound and a mouth phenolic compound, the extract containing almost no anthraquinones and a remarkable effect of improving hyperglycemia. .
- the present invention is a plant sterol that can be safely ingested, can be used as a material for foods for preventing lifestyle-related diseases, has extremely low contamination with anthraquinones, and can be added to foods. It is an object of the present invention to provide an Aloe vera extract containing a cyclolanostani compound and a mouth phenol compound, and a method for producing the Aloe vera extract.
- Another object of the present invention is to provide a hyperglycemia improving agent comprising the aloe vera extract as an active ingredient.
- the first invention of the present application for solving the above-mentioned problems includes Aloe vera having the following properties 1) and Z or 2), containing 1.0% by mass or more of a mixture comprising a cyclolanostane compound and an oral phenol compound. It is an extract.
- the content of the anthraquinone compound is 0.001% by mass or less.
- the aloe vera extract is also referred to as “the aloe vera extract of the present invention”.
- the first invention of the present application preferably uses the following 3) and Z or 4) as an embodiment.
- Mouth phenol compounds are 4-methylcholestho 7-en-3-ol, 4-methylell Must be one or more compounds selected from Gosto 7-Yen 3-ol, 4-Methylstigmasto 7-Yen 3-ol.
- a second invention of the present application for solving the above-mentioned problems is a food or drink containing the aloe vera extract of the first invention of the present application.
- the preferred embodiment of the Aloe vera extract in the food or drink of the present invention is the same as in the first invention of the present application. Moreover, the preferable content of the Aloe vera extract in the food and drink is
- the third invention of the present application for solving the above-mentioned problems is that the mesophyll part not containing aloe vera leaf skin is freeze-dried or hot-air dried to remove water to prepare powdered aloe vera mesophyll, and from the prepared powder aloe vera mesophyll
- the Aloe vera extract is a method for producing an Aloe vera extract by a supercritical extraction method based on the following conditions a ).
- the extraction solvent is carbon dioxide
- the extraction time is 50 to 70 minutes.
- the fourth invention of the present application for solving the above-mentioned problem is an antihyperglycemic agent comprising an aloe vera extract containing 1.0% by mass or more of a mixture comprising a cyclolanostane compound and an oral phenol compound as an active ingredient, Aloe vera extract has the following properties 5) and Z or 6).
- the content of the anthraquinone compound is 0.001% by mass or less.
- the fourth invention of the present application has the following 7) and Z or 8) as preferred embodiments.
- the oral phenol compound is selected from 4-methylcholest-7-en-3-ol, 4-methyl ergost 7-en 3-ol, 4-methyl stigmast 7-en 3-ol One or more selected compounds.
- the fifth invention of the present application for solving the above-mentioned problem is an aloe vera extract containing 1.0% by mass or more of a mixture comprising cyclolanostani compound and oral phenol compound for the production of a hyperglycemia-improving agent.
- the aloe vera extract has the following properties 9) and Z or 10).
- the content of the anthraquinone compound is 0.001% by mass or less.
- the fifth invention of the present application has the following 11) and Z or 12) as preferred embodiments.
- One or more oral phenolic compounds selected from 4-methylcholest-7en-3ol, 4-methylergost-7-en-3-ol, 4-methylstigmast 7-en-3-ol It must be a compound of
- the sixth invention of the present application for solving the above-mentioned problem is to improve the high blood glucose level by increasing the aloe vera extract containing 1.0% by mass or more of a mixture of cyclolanostane compound and oral phenolic compound.
- the content of the anthraquinone compound is 0.001% by mass or less.
- the aloe vera extract of the present invention is safe and has a remarkable effect of improving hyperglycemia, and can be used as a material for functional foods, particularly foods for specified health use.
- anthraquinones anthraquinone compounds
- the aloe vera extract of the present invention does not contain any substances that are not suitable as food additives such as organic solvents, and therefore can be applied to any food.
- the production method provided by the present invention makes it possible to provide a material suitable for the development of functional foods using aloe vera. Promoted.
- the content of the mixture composed of the cyclolanostane compound and the oral phenol compound is 1.0% by mass or more, preferably 1.2% by mass or more, more preferably 2.0% by mass. % Or more.
- the cyclolanostane compound is a compound represented by the following general formula (1) (a compound having a cyclolanostan skeleton).
- R1 represents a linear or branched alkyl group having 6 to 8 carbon atoms, a alkenyl group containing one or two double bonds, or an alkyl thereof.
- one or two of the hydrogen atoms of the alkyl group and the alkyl group is a substituted alkyl group or a substituted alkenyl group substituted with a hydroxyl group and a Z or carbo col group
- R2 and R3 are each independently a hydrogen atom or It is a methyl group
- R1 is preferably any one of the groups represented by the following formulae.
- R a is a hydrogen atom, a hydroxyl group or a methyl group
- R b is a hydrogen atom or a hydroxyl group
- Rc is a hydrogen atom, a hydroxyl group or a methyl group
- the oral phenol compound is a compound represented by a compound represented by the following general formula (2) (compound having oral phenol skeleton).
- R1 is a linear or branched alkyl group having 5 to 16 carbon atoms, or a alkenyl group containing one or two double bonds.
- the alkyl group or alkenyl group may be a substituted alkyl group or a substituted alkenyl group in which at least one hydrogen atom is substituted with a hydroxyl group and Z or a carboxylic group.
- the alkyl group having 1 to 3 carbon atoms is methyl.
- a methyl group which is preferably a group or an ethyl group.
- R1 is preferably any one of the groups represented by the following formulae.
- R a and R b are either one of H, —OH, or —CH 3.
- R a and R b are either one of H, —OH, or —CH 3.
- R c and R d are either one of H, —OH, or —CH 3.
- cyclolanostane compounds include 9, 19 cyclolanostane 1-ol (the following formula (3)), and Z or 24-methylene 9, 19-cyclolanostan-3 all (the following formula (4)) are preferred phenol compounds such as 4-methylcholest-7-en-3-ol (the following formula (5)), 4-methylergost 7-en-3-ol (the following formula (6) ), 4-methyl stigmast 7-en 3 ol (1 or a plurality of compounds selected from the following formula (7)).
- the aloe vera extract of the present invention is an anthraquinone compound such as aloenin, barbaroin, aloe emodin, etc. (in the present invention, sometimes referred to as "anthraquinones”), which is a practical problem.
- anthraquinones such as aloenin, barbaroin, aloe emodin, etc.
- these compounds have a relaxing action, their content is preferably small.
- the aloenin and barbaroin are preferably 0.001% by mass or less and more preferably 0.0003% by mass or less. It is particularly preferable not to contain it. Also, aloe emodin is preferably 0.001% by mass or less, more preferably 0.0003% by mass or less, and most preferably 0.00028% by mass or less.
- the aloe vera extract of the present invention can be produced by the following method using aloe vera (Aloe barbade nisis Miller), which belongs to the genus Aloe family, as a starting material.
- aloe vera Aloe barbade nisis Miller
- an extract equivalent to the aloe vera extract of the present invention can be obtained by obtaining the extract of the succulent plant such as aloe arborescen miller var. Natalensis Berger as a starting material. It is also possible to produce things.
- aloe vera when an aloe vera leaf is sliced horizontally, the outer wall of the epidermis covered with a thick cuticle appears. Below the epidermis is mesophyll differentiated into green tissue cells and cells with thin cell walls known as parenchyma. The parenchyma cells collect and collect a transparent mucus-like jelly. Vascular bundles with internal vascular sheath cells contain a yellow juice with laxative properties and are sandwiched between two large cells. Aloe vera has two main liquid sources: yellow latex (leachate) and clear gel (mucus). Transparent gel of soft tissue cell power of the plant ( (Mucus) is especially called aloe vera gel.
- aloe vera leaves have three distinct parts: 1) yellow juice, mainly anthraquinones (anthraquinones); 2) internal gel matrix or “meat”; and 3) It is the “skin (leaf skin)” that also has the outer skin, tip, base and spine force.
- the aloe vera extract of the present invention is preferably produced by a supercritical extraction method. Specifically, a mesophyll (transparent gel) part not containing aloe vera leaf skin is freeze-dried or hot-air dried to prepare powdered aloe vera mesophyll, and from the prepared powder aloe vera mesophyll, the following (a) to (e) Based on the above conditions, it is produced by the supercritical extraction method.
- the extraction solvent is carbon dioxide
- the extraction time is 50 to 70 minutes.
- the extraction solvent supercritical propane, supercritical ethylene, supercritical 1, 1, 1 have the viewpoint power to improve the extraction efficiency of cyclolanostani compound and oral phenol compound. , 2-Tetrafluoretane, etc. is also possible. The power of improving the safety of foods and drinks is better using carbon dioxide.
- the extraction temperature can be appropriately selected within a temperature range of 28 ° C to 120 ° C. The extraction efficiency of cyclolanostane compounds and oral phenol compounds is improved, and anthraquinone compounds (for example, aloe emodin) are used. ) Is preferably in the range of 50 to 69 ° C, more preferably in the range of 50 to 59 ° C.
- the pressure can be appropriately selected within the range of 5.5 to 60 MPa. Improves the extraction efficiency of cyclolanostane compound and oral phenol compound, and content of anthraquinone compound In order to reduce this, the range of 15 to 60 Mpa is preferable, and the range of 15 to 24 Mpa is more preferable.
- an entrainer for ethanol or the like.
- Anthraquinone From the viewpoint of reducing the content of the compound, it is preferable not to use an entrainer.
- the aloe vera extract of the present invention has an action of lowering the value of hemoglobin Ale, and as a result, can control blood glucose levels for a long period of time. Therefore, the aloe vera extract of the present invention can be used as an active ingredient of a hyperglycemia improving agent.
- the content of the cyclolanostane compound, the oral phenol compound, and the anthraquinone compound of the hyperglycemia improving agent of the present invention is the same as that of the aloe vera extract of the present invention.
- the aloe vera extract of the present invention can be used as an active ingredient of a pharmaceutical or a food or drink (beverage or food) for improving hyperglycemia.
- the medicament for improving hyperglycemia containing the aloe vera extract of the present invention is the aloe vera extract of the present invention as it is, or these are formulated pharmaceutically. It can be produced in combination with an acceptable pharmaceutical carrier, and can be administered to mammals including humans orally or parenterally.
- the cyclolanostane compound and the Z or oral phenol compound in the Aloe vera extract can be crushed by pharmaceutically acceptable salt.
- Pharmaceutically acceptable salts include both metal salts (inorganic salts) and organic salts, a list of which is given in “Remington's Pharmaceutical Sciences”, 17th edition, page 1418.
- inorganic acid salts such as hydrochloride, sulfate, phosphate, diphosphate and hydrobromide, malate, maleate, fumarate, tartrate, succinate,
- Organic salts such as citrate, acetate, lactate, methanesulfonate, ⁇ -toluenesulfonate, pamoate, salicylate and stearate are included without limitation.
- it may be a salt of a metal such as sodium, potassium, calcium, magnesium or aluminum, or a salt with an amino acid such as lysine.
- cyclanostany compounds in aloe vera extract and solvates such as hydrates of coconut or oral phenol compounds or pharmaceutically acceptable salts thereof.
- the pharmaceutical formulation of the present invention is not particularly limited and can be appropriately selected depending on the purpose of treatment. Specifically, tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules Examples include suppositories, syrups, suppositories, injections, ointments, patches, eye drops, and nasal drops.
- Additives such as solvent for additives Can be used.
- the aloe vera extract of the present invention may be used in combination with other drugs having an action for improving hyperglycemia.
- the amount of the Aloe vera extract of the present invention contained in the medicament of the present invention is not particularly limited and may be appropriately selected.
- the amount of the resulting mixture is 0.001 to 10% by mass, preferably 0.01 to 1% by mass in the preparation.
- the medicament of the present invention is useful for the treatment or prevention of diseases caused by a hyperglycemic state, such as diabetes and preglycosuria (a state suspected of being diabetic).
- hyperglycemic power can also be used to prevent the development of diabetes.
- the medicament of the present invention can treat or prevent various diseases caused by hyperglycemic conditions and reduce the risk of these diseases.
- diseases and complications resulting from intense hyperglycemia include diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, diabetic gangrene, stroke due to diabetes, myocardial infarction due to diabetes, etc. Can be illustrated.
- the hyperglycemic state is a state in which the blood glucose level is outside the normal region, and the normal region is generally a fasting blood glucose level of llOmgZdl or less and 1 hour after 75g sugar load.
- the blood glucose level is defined as 160 mgZdl or less and the blood glucose level after 2 hours is 120 mgZdl or less (Japan Clinical, Vol.806, No.1, pages 28-35, 2002).
- the medicament of the present invention is suitably used for treatment of a patient whose hemoglobin Ale value is higher than that of a healthy person, for example, a patient whose hemoglobin Ale value is 5.8% or more.
- the administration timing of the medicament of the present invention is not particularly limited, and it is possible to appropriately select the administration timing according to the treatment method for the target disease.
- the dosage form is preferably determined according to the dosage form, the patient's age, sex, other conditions, the degree of symptoms of the patient, and the like.
- the dosage of the active ingredient of the medicament of the present invention is appropriately selected depending on the usage, patient age, sex, disease severity, other conditions and the like.
- the amount of mixture of cyclolanostani compound and oral phenol compound is preferably 0.001 to 50 mgZkgZ days, more preferably 0.01 to lmgZkgZ days. .
- the dry mass of the aloe vera extract of the present invention is preferably 0.1 to: LOOOmgZkgZ days, more preferably 1 ⁇ : L00mg / kg / day should be used as a guideline.
- the medicament of the present invention can be administered once a day or divided into a plurality of times.
- the aloe vera extract or the like of the present invention can also be contained in a food or drink.
- the food or drink is not particularly limited as long as the effect of the active ingredient is not impaired.
- the content of the Aloe vera extract in the food and drink of the present invention is not particularly limited as long as the effect of the active ingredient can be obtained, but 0.01 to 50% by mass is preferable, and 0.01 to 20% by mass is preferable. Particularly preferred.
- the food / beverage products of this invention can be manufactured by a normal method using the raw material normally used for food / beverage products except containing the said active ingredient.
- hyperglycemia improvement means to improve or prevent various health hazards caused by hyperglycemia.
- hyperglycemia prevention “suppression of increase in blood glucose level”, “improvement of increase in blood glucose level”, “prevention of increase in blood glucose level” and the like are also exemplified in the present invention as the same meaning as “improvement of hyperglycemia”. be able to.
- the food and drink of the present invention are useful for the treatment or prevention of diseases caused by hyperglycemic conditions such as diabetes and pre-diabetes (a state suspected of being diabetic).
- hyperglycemic status can also be used to prevent the development of diabetes.
- the food and drink of the present invention can treat or prevent various diseases and complications caused by hyperglycemia, and can reduce the risk of these diseases and complications.
- Various diseases caused by such hyperglycemia 'Complications include diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, diabetic gangrene, stroke caused by diabetes, myocardial infarction caused by diabetes, etc. Can be illustrated.
- the food / beverage product of the present invention is a food / beverage product whose use is indicated for improving hyperglycemia, for example, a food / beverage product containing a compound having a hyperglycemic improvement effect displayed as "for hyperglycemia improvement”. It is preferable to sell the product as “a product” or “a food and drink containing a plant extract that is indicated for improving hyperglycemia”.
- the aloe vera extract of the present invention has an action to improve hyperglycemia. That is, the display of improvement in hyperglycemia is considered to have a meaning of suppressing an increase in blood sugar. Therefore, the food / beverage products of the present invention can display “for suppressing blood sugar elevation”. That is, the display for improving hyperglycemia may be such a display for “suppressing blood sugar elevation”.
- the wording used for the display as described above is not limited to the words “for improving hyperglycemia” or “for suppressing blood sugar rise”, but other words. However, it is needless to say that any word representing an effect of improving hyperglycemia or suppressing an increase in blood glucose level is included in the scope of the present invention. As such a wording, for example, it is possible to display based on various uses that allow the consumer to recognize the effect of improving hyperglycemia or suppressing increase in blood glucose level. For example, it is possible to exemplify indications such as “suitable for those who have begun to worry about blood sugar levels” and “reduction of risk factors (risks) of lifestyle-related diseases such as diabetes”.
- the "display” means all actions for informing the consumer of the use, and if the display can recall and analogize the use, the purpose of the display, the display Regardless of the content, the object to be displayed, the medium, etc., all correspond to the “display” of the present invention. However, it is preferable to display it in such an expression that the consumer can directly recognize the use.
- the act of describing the above-mentioned use in the product or the product packaging relating to the food or drink of the present invention the product or the product packaging describing the above-mentioned use is transferred, and displayed for delivery, transfer or delivery Display or distribute the above uses in the acts of importing, advertisements on products, price lists or transaction documents, or distributing them, or describing the above uses in the contents of these information (such as the Internet) ) Examples of activities provided by the method.
- the display is a display approved by the government or the like (for example, a display that is approved based on various systems determined by the government and is performed in a mode based on such approval).
- a display that is approved based on various systems determined by the government and is performed in a mode based on such approval In particular, it is preferable to display on materials such as packaging, containers, catalogs, pamphlets, POP, etc., and other documents.
- indications such as health foods, functional foods, enteral nutritional foods, special-purpose foods, nutritional functional foods, quasi-drugs, etc. can be exemplified.
- a label approved by a specific health food or similar system can be exemplified. Examples of the latter include labeling as food for specified health use, labeling as conditionally specified food for specified health use, labeling that affects the structure and function of the body, labeling for reducing disease risk, etc.
- Speaking of health promotion law enforcement regulations (April 30, 2003 Ministry of Health, Labor and Welfare Ordinance No. 86) labeling as food for specified health use (especially labeling of health use), and similar
- the display can be listed as a typical example.
- LC-MS manufactured by Shimadzu Corporation
- brush castrol manufactured by Wako Pure Chemical Industries, Ltd.
- an internal standard substance which is a cyclolanostani compound 9, 19 Cyclolanostan 1-ol, 24-Methylene 1 9, 19 Cyclolanostan 1-ol, and oral phenolic compounds 4-methylcholestho 7-en-3-ol, 4-methylergost 1
- the total amount of aloe vera extract extracted was greater when prepared by the organic solvent extraction method than when prepared by the supercritical extraction method.
- the content of the mixture of cyclolanostany compound and oral phenolic compound with respect to aloe vera extract is generally the same as the aloe vera extract prepared by the organic solvent extraction method using the aloe vera extract prepared by the supercritical extraction method. It was found to be more than 10 times higher than
- the test sample was prepared by adjusting with a DMSO aqueous solution so that the concentration of the mixture consisting of the substances was 1 ⁇ g / ml).
- the final DMSO concentration at this time was adjusted with physiological saline so as to be 0.2%.
- the mesophyll portion was collected, and the recovered mesophyll portion was crushed with a juicer mixer, and the aloe vera pressing solution from which fibrous precipitate was removed was used as a control sample.
- 0.2% DMSO aqueous solution was used as a negative sample.
- mice As type II diabetes model mice, 6-week-old male dbZdb mice (purchased from CLEA Japan) were used, and the mice were divided into 7 groups per group. Each group was orally administered daily for 34 days with 1 ml of test sample, control sample, and negative sample once a day using a sonde. On day 35 after the start of administration, hemoglobin Ale was measured with DCA2000 (manufactured by Bayer Sankyo).
- mice administered with the test sample had an activity to improve hyperglycemia, with a hemoglobin Ale value decreased by 30% or more compared to the negative sample administration group.
- a hemoglobin Ale value decreased by 30% or more compared to the negative sample administration group.
- the aloe vera extract of the invention (supercritical extract) was calculated from its effective amount and was found to be 13,000 times more effective than the aloe vera press. In addition, no significant pathological side effects were observed in the mice to which the test sample was administered.
- the leaf skin was peeled off to recover the mesophyll (transparent gel) portion, and the recovered mesophyll portion was freeze-dried to prepare 300 g of aloe vera mesophyll powder.
- Extraction was performed by supercritical extraction using 20 g of the prepared aloe vera mesophyll powder.
- JASCO CO delivery pump SCF-GET
- PU-2080 pump PU-2080
- composition of the produced aloe vera extract was analyzed using LC-MS.
- the cyclolanostane compounds 9, 19 cyclolanostane 1-ol and 24-methylene 9, 19 were obtained.
- a pharmaceutical having the effect of improving hyperglycemia of a tablet having the following compositional power was produced by the following method.
- Lactose (Morinaga Milk Industry Co., Ltd.) 18.5
- Carboxymethylcellulose calcium (Gotoku Pharmaceutical Co., Ltd.) 9.4
- Aloe vera extract dried product
- lactose lactose
- corn starch carboxymethyl cellulose
- carboxymethyl cellulose Calcium cellulose was mixed uniformly with sterilized purified water, and dried at 50 ° C for 3 hours.
- Magnesium stearate is added to the dried product, mixed, and compressed into tablets by a conventional method.
- a tablet containing about 0.5% by mass in the preparation is prepared. Obtained.
- Whey protein degradation product manufactured by Morinaga Milk Industry Co., Ltd. 10. 8 kg, dextrin (manufactured by Showa Sangyo Co., Ltd.) 36 kg, and a small amount of water-soluble vitamins and minerals dissolved in 200 kg of water, and the aqueous phase was prepared in the tank. Made.
- soybean salad oil (manufactured by Taiyo Yushi Co., Ltd.) 3 kg
- palm oil (manufactured by Taiyo Yushi Co., Ltd.) 8.5 kg
- safflower oil (manufactured by Taiyo Yufu Co., Ltd.) 2.5 kg
- lecithin (manufactured by Ajinomoto Co.) 0.2 kg
- Fatty acid monoglyceride (manufactured by Kao Corporation) 0.2 kg and a small amount of fat-soluble vitamin were mixed and dissolved to prepare an oil phase.
- the oil phase was added to the aqueous phase in the tank, mixed with stirring, then heated to 70 ° C, and further homogenized at a pressure of 14.7 MPa with a homogenizer. Next, after sterilizing at 90 ° C for 10 minutes, it was concentrated and spray-dried to prepare about 59 kg of intermediate product powder.
- the aloe vera extract of the present invention is safe and has a remarkable effect of improving hyperglycemia, and can be used as a material for functional foods, particularly foods for specified health use. ) Can be ingested as food, and can be applied to all foods. Furthermore, the production method provided by the present invention makes it possible to provide a material suitable for the development of functional foods using Aloe vera, and promotes the use of Aloe Vera for foods.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/815,428 US20090004307A1 (en) | 2005-11-25 | 2006-11-20 | Aloe Vera Extract, Method of Producing Aloe Vera Extract, and Hyperglycemia Improving Agent |
AU2006317258A AU2006317258B2 (en) | 2005-11-25 | 2006-11-20 | Aloe vera extract, method of producing aloe vera extract, and hyperglycemia improving agent |
JP2007546430A JP4095115B2 (ja) | 2005-11-25 | 2006-11-20 | アロエベラ抽出物、アロエベラ抽出物の製造方法、高血糖改善剤 |
EP06823482.2A EP1952817B1 (en) | 2005-11-25 | 2006-11-20 | Aloe vera extract, method of producing aloe vera extract, and hyperglycemia improving agent |
CA2602066A CA2602066C (en) | 2005-11-25 | 2006-11-20 | Aloe vera extract, method of producing aloe vera extract, and hyperglycemia improving agent |
CN200680006127.8A CN101128211B (zh) | 2005-11-25 | 2006-11-20 | 翠叶芦荟提取物、制备翠叶芦荟提取物的方法和高血糖改善剂 |
ES06823482T ES2425149T3 (es) | 2005-11-25 | 2006-11-20 | Extracto de Aloe vera, método de preparación de extracto de Aloe vera y agente mejorador de la hiperglucemia |
US12/840,122 US8877265B2 (en) | 2005-11-25 | 2010-07-20 | Method of producing aloe vera extract |
US13/680,658 US8709512B2 (en) | 2005-11-25 | 2012-11-19 | Method for treating hyperglycemia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-340245 | 2005-11-25 | ||
JP2005340245 | 2005-11-25 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/815,428 A-371-Of-International US20090004307A1 (en) | 2005-11-25 | 2006-11-20 | Aloe Vera Extract, Method of Producing Aloe Vera Extract, and Hyperglycemia Improving Agent |
US81542807A A-371-Of-International | 2005-11-25 | 2007-08-02 | |
US12/840,122 Division US8877265B2 (en) | 2005-11-25 | 2010-07-20 | Method of producing aloe vera extract |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007060911A1 true WO2007060911A1 (ja) | 2007-05-31 |
Family
ID=38067138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/323095 WO2007060911A1 (ja) | 2005-11-25 | 2006-11-20 | アロエベラ抽出物、アロエベラ抽出物の製造方法、高血糖改善剤 |
Country Status (10)
Country | Link |
---|---|
US (3) | US20090004307A1 (ja) |
EP (2) | EP1952817B1 (ja) |
JP (1) | JP4095115B2 (ja) |
KR (1) | KR100897492B1 (ja) |
CN (2) | CN103494998B (ja) |
AU (1) | AU2006317258B2 (ja) |
CA (1) | CA2602066C (ja) |
ES (2) | ES2425149T3 (ja) |
RU (1) | RU2356572C1 (ja) |
WO (1) | WO2007060911A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010058795A1 (ja) | 2008-11-19 | 2010-05-27 | 森永乳業株式会社 | 抗酸化剤 |
WO2011096122A1 (ja) | 2010-02-03 | 2011-08-11 | 森永乳業株式会社 | アロエパウダーの製造方法 |
WO2015015815A1 (ja) * | 2013-07-30 | 2015-02-05 | 森永乳業株式会社 | 繊維芽細胞賦活剤 |
WO2015015816A1 (ja) * | 2013-07-30 | 2015-02-05 | 森永乳業株式会社 | 繊維芽細胞賦活剤 |
WO2015141787A1 (ja) * | 2014-03-20 | 2015-09-24 | 森永乳業株式会社 | アロエ抽出物の製造方法及びアロエ抽出物 |
WO2016084957A1 (ja) * | 2014-11-28 | 2016-06-02 | 森永乳業株式会社 | マトリックスメタロプロテアーゼ産生阻害剤 |
JP2019043863A (ja) * | 2017-08-30 | 2019-03-22 | 森永乳業株式会社 | Ucp発現促進剤 |
JP2020083851A (ja) * | 2018-11-30 | 2020-06-04 | 森永乳業株式会社 | アロエ抽出物の製造方法 |
JPWO2021193418A1 (ja) * | 2020-03-24 | 2021-09-30 | ||
WO2022045354A1 (ja) * | 2020-08-31 | 2022-03-03 | 森永乳業株式会社 | 植物ステロール原料の製造方法 |
WO2023054477A1 (ja) * | 2021-09-28 | 2023-04-06 | 森永乳業株式会社 | アロエ抽出物の製造方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100998858B1 (ko) * | 2004-03-31 | 2010-12-08 | 모리나가 뉴교 가부시키가이샤 | 고혈당 개선용 음식품 |
EP2377875B1 (en) * | 2008-11-19 | 2020-09-02 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
DE102012222365A1 (de) | 2012-12-05 | 2014-06-05 | Aesculap Ag | Zusammensetzung zur Anwendung bei der Prophylaxe von post-chirurgischen Adhäsionen |
KR101520934B1 (ko) * | 2013-12-30 | 2015-05-18 | 건국대학교 산학협력단 | 항산화능이 강화된 알로에 베라 추출물의 제조 방법 |
EP3225241A4 (en) * | 2014-11-28 | 2018-08-15 | Morinaga Milk Industry Co., Ltd. | Agent for preventing or improving symptoms caused by imbalance of sex hormones |
JP7239489B2 (ja) | 2017-12-19 | 2023-03-14 | 森永乳業株式会社 | アロエ粉末の製造方法 |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5718617A (en) | 1980-07-07 | 1982-01-30 | Morishita Seiyaku Kk | Antilipemic agent |
JPS60214741A (ja) | 1984-04-05 | 1985-10-28 | Toyo Yakushiyoku Kogyo Kk | 血糖降下剤 |
JPH08208495A (ja) | 1995-02-06 | 1996-08-13 | Nonogawa Shoji Kk | 免疫抑制改善剤 |
JP2832551B2 (ja) | 1988-01-14 | 1998-12-09 | カーリントン ラボラトリーズ インコーポレーテッド | アロエ製品の製造方法 |
WO1999011144A1 (en) | 1997-09-02 | 1999-03-11 | The Ricex Company, Inc. | A method for treating hypercholesterolemia, hyperlipidemia, and atherosclerosis |
JP2000319190A (ja) | 1999-05-10 | 2000-11-21 | Nonogawa Shoji Kk | 肥満の予防改善剤 |
JP2002068997A (ja) | 2000-08-23 | 2002-03-08 | Air Green Co Ltd | アロエベラ原液とその濃縮液 |
JP2002205955A (ja) | 2001-01-05 | 2002-07-23 | Daily Foods Kk | 無色透明、無添加、アロイン除去の100%アロエベラ圧搾液 |
JP2002284661A (ja) | 2001-03-27 | 2002-10-03 | Daily Foods Kk | アロエベラ圧搾液 |
JP2002542161A (ja) | 1999-04-09 | 2002-12-10 | コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト | 植物ステロールを回収する方法 |
JP2002371003A (ja) | 2001-06-15 | 2002-12-26 | Kikkoman Corp | 血糖値上昇抑制剤 |
JP2003095941A (ja) | 2001-09-26 | 2003-04-03 | Ito En Ltd | 糖質消化酵素阻害剤、血糖値上昇抑制剤、肥満治療予防剤、糖尿病治療予防剤、健康飲食物 |
JP2003113394A (ja) | 2001-10-04 | 2003-04-18 | Unitika Ltd | こんにゃく抽出物及びそれを含有する飲食品 |
JP2003277269A (ja) | 2002-03-20 | 2003-10-02 | Univ Nihon | 発癌予防剤 |
JP2003286185A (ja) | 2002-03-29 | 2003-10-07 | Daily Foods Kk | アロエベラ圧搾液及び該圧搾液を有効成分とする血糖値降下剤 |
JP2005087998A (ja) | 2003-08-27 | 2005-04-07 | Malaysian Palm Oil Board | カロテン濃縮物、ビタミンe濃縮物及びその他の微量成分濃縮物の一段階及び二段階超臨界流体抽出 |
WO2005094838A1 (ja) * | 2004-03-31 | 2005-10-13 | Morinaga Milk Industry Co., Ltd. | 高血糖改善のための医薬及び飲食品 |
WO2006035525A1 (ja) * | 2004-09-29 | 2006-04-06 | Morinaga Milk Industry Co., Ltd. | 高血糖改善のための医薬及び飲食品 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4801582A (en) | 1984-04-05 | 1989-01-31 | Toyo Yakushoku Kogyo Co., Ltd. | Method and composition for treating hypoglycemia using aloe polysaccharides |
JP2844520B2 (ja) | 1995-03-20 | 1999-01-06 | カーリントン ラボラトリーズ インコーポレーテッド | アロエジュースの製造方法 |
US5929051A (en) * | 1998-05-13 | 1999-07-27 | Carrington Laboratories, Inc. | Aloe pectins |
JP4846990B2 (ja) * | 2003-08-06 | 2011-12-28 | 株式会社テラ・ブレインズ | アディポネクチン分泌促進剤 |
MY146635A (en) * | 2004-09-01 | 2012-09-14 | Malaysian Palm Oil Board | Specialty palm oil products and other specialty vegetable oil products |
-
2006
- 2006-11-20 EP EP06823482.2A patent/EP1952817B1/en active Active
- 2006-11-20 CN CN201310334787.0A patent/CN103494998B/zh active Active
- 2006-11-20 RU RU2007137518/15A patent/RU2356572C1/ru not_active IP Right Cessation
- 2006-11-20 KR KR1020077018270A patent/KR100897492B1/ko active IP Right Grant
- 2006-11-20 ES ES06823482T patent/ES2425149T3/es active Active
- 2006-11-20 WO PCT/JP2006/323095 patent/WO2007060911A1/ja active Application Filing
- 2006-11-20 CA CA2602066A patent/CA2602066C/en active Active
- 2006-11-20 EP EP10157399.6A patent/EP2206509B1/en active Active
- 2006-11-20 ES ES10157399.6T patent/ES2576845T3/es active Active
- 2006-11-20 JP JP2007546430A patent/JP4095115B2/ja active Active
- 2006-11-20 US US11/815,428 patent/US20090004307A1/en not_active Abandoned
- 2006-11-20 CN CN200680006127.8A patent/CN101128211B/zh active Active
- 2006-11-20 AU AU2006317258A patent/AU2006317258B2/en active Active
-
2010
- 2010-07-20 US US12/840,122 patent/US8877265B2/en active Active
-
2012
- 2012-11-19 US US13/680,658 patent/US8709512B2/en active Active
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5718617A (en) | 1980-07-07 | 1982-01-30 | Morishita Seiyaku Kk | Antilipemic agent |
JPS60214741A (ja) | 1984-04-05 | 1985-10-28 | Toyo Yakushiyoku Kogyo Kk | 血糖降下剤 |
JP2832551B2 (ja) | 1988-01-14 | 1998-12-09 | カーリントン ラボラトリーズ インコーポレーテッド | アロエ製品の製造方法 |
JPH08208495A (ja) | 1995-02-06 | 1996-08-13 | Nonogawa Shoji Kk | 免疫抑制改善剤 |
WO1999011144A1 (en) | 1997-09-02 | 1999-03-11 | The Ricex Company, Inc. | A method for treating hypercholesterolemia, hyperlipidemia, and atherosclerosis |
JP2002542161A (ja) | 1999-04-09 | 2002-12-10 | コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト | 植物ステロールを回収する方法 |
JP2000319190A (ja) | 1999-05-10 | 2000-11-21 | Nonogawa Shoji Kk | 肥満の予防改善剤 |
JP2002068997A (ja) | 2000-08-23 | 2002-03-08 | Air Green Co Ltd | アロエベラ原液とその濃縮液 |
JP2002205955A (ja) | 2001-01-05 | 2002-07-23 | Daily Foods Kk | 無色透明、無添加、アロイン除去の100%アロエベラ圧搾液 |
JP2002284661A (ja) | 2001-03-27 | 2002-10-03 | Daily Foods Kk | アロエベラ圧搾液 |
JP2002371003A (ja) | 2001-06-15 | 2002-12-26 | Kikkoman Corp | 血糖値上昇抑制剤 |
JP2003095941A (ja) | 2001-09-26 | 2003-04-03 | Ito En Ltd | 糖質消化酵素阻害剤、血糖値上昇抑制剤、肥満治療予防剤、糖尿病治療予防剤、健康飲食物 |
JP2003113394A (ja) | 2001-10-04 | 2003-04-18 | Unitika Ltd | こんにゃく抽出物及びそれを含有する飲食品 |
JP2003277269A (ja) | 2002-03-20 | 2003-10-02 | Univ Nihon | 発癌予防剤 |
JP2003286185A (ja) | 2002-03-29 | 2003-10-07 | Daily Foods Kk | アロエベラ圧搾液及び該圧搾液を有効成分とする血糖値降下剤 |
JP2005087998A (ja) | 2003-08-27 | 2005-04-07 | Malaysian Palm Oil Board | カロテン濃縮物、ビタミンe濃縮物及びその他の微量成分濃縮物の一段階及び二段階超臨界流体抽出 |
WO2005094838A1 (ja) * | 2004-03-31 | 2005-10-13 | Morinaga Milk Industry Co., Ltd. | 高血糖改善のための医薬及び飲食品 |
WO2006035525A1 (ja) * | 2004-09-29 | 2006-04-06 | Morinaga Milk Industry Co., Ltd. | 高血糖改善のための医薬及び飲食品 |
Non-Patent Citations (8)
Title |
---|
FOOD CHEMISTRY, vol. 91, 2004, pages 85 - 90 |
HU Q. ET AL.: "Free radical-scavenging activity of Aloe vera (Aloe barbadensis Miller) extracts by supercritical carbon dioxide extraction", FOOD CHEMISTRY, vol. 91, no. 1, 2004, pages 85 - 90, XP004654102 * |
NIPPON RINSHO, NO. 808, vol. 2, 2002, pages 405 - 409 |
PHYTOMEDICINE, vol. 3, 1996, pages 245 - 248 |
PHYTOTHERAPY RESEARCH, vol. 15, 2001, pages 157 - 161 |
PHYTOTHERAPY RESEARCH, vol. 7, 1993, pages 37 - 42 |
See also references of EP1952817A1 |
TANAKA M. ET AL.: "Identification of five phytosterols from Aloe vera gel as anti-diabetic compounds", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 29, no. 7, July 2006 (2006-07-01), pages 1418 - 1422, XP003011592 * |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010058795A1 (ja) | 2008-11-19 | 2010-05-27 | 森永乳業株式会社 | 抗酸化剤 |
JP4590491B2 (ja) * | 2008-11-19 | 2010-12-01 | 森永乳業株式会社 | 過酸化脂質生成抑制のための医薬 |
JPWO2010058795A1 (ja) * | 2008-11-19 | 2012-04-19 | 森永乳業株式会社 | 過酸化脂質生成抑制のための医薬 |
US8470807B2 (en) | 2008-11-19 | 2013-06-25 | Morinaga Milk Industry Co., Ltd. | Antioxidant |
KR101405574B1 (ko) * | 2008-11-19 | 2014-06-10 | 모리나가 뉴교 가부시키가이샤 | 항산화제 |
KR101468853B1 (ko) | 2008-11-19 | 2014-12-03 | 모리나가 뉴교 가부시키가이샤 | 항산화제 |
WO2011096122A1 (ja) | 2010-02-03 | 2011-08-11 | 森永乳業株式会社 | アロエパウダーの製造方法 |
JPWO2011096122A1 (ja) * | 2010-02-03 | 2013-06-10 | 森永乳業株式会社 | アロエパウダーの製造方法 |
WO2015015815A1 (ja) * | 2013-07-30 | 2015-02-05 | 森永乳業株式会社 | 繊維芽細胞賦活剤 |
WO2015015816A1 (ja) * | 2013-07-30 | 2015-02-05 | 森永乳業株式会社 | 繊維芽細胞賦活剤 |
WO2015141787A1 (ja) * | 2014-03-20 | 2015-09-24 | 森永乳業株式会社 | アロエ抽出物の製造方法及びアロエ抽出物 |
JP6066537B2 (ja) * | 2014-03-20 | 2017-01-25 | 森永乳業株式会社 | アロエ抽出物の製造方法及びアロエ抽出物 |
US10398162B2 (en) | 2014-03-20 | 2019-09-03 | Morinaga Milk Industry Co., Ltd. | Method for manufacturing aloe extract, and aloe extract |
WO2016084957A1 (ja) * | 2014-11-28 | 2016-06-02 | 森永乳業株式会社 | マトリックスメタロプロテアーゼ産生阻害剤 |
JP2019043863A (ja) * | 2017-08-30 | 2019-03-22 | 森永乳業株式会社 | Ucp発現促進剤 |
JP2020083851A (ja) * | 2018-11-30 | 2020-06-04 | 森永乳業株式会社 | アロエ抽出物の製造方法 |
JP7245637B2 (ja) | 2018-11-30 | 2023-03-24 | 森永乳業株式会社 | アロエ抽出物の製造方法 |
JPWO2021193418A1 (ja) * | 2020-03-24 | 2021-09-30 | ||
WO2021193418A1 (ja) * | 2020-03-24 | 2021-09-30 | 森永乳業株式会社 | 超臨界流体抽出装置及びそれを用いた目的物の製造方法 |
WO2022045354A1 (ja) * | 2020-08-31 | 2022-03-03 | 森永乳業株式会社 | 植物ステロール原料の製造方法 |
JPWO2022045354A1 (ja) * | 2020-08-31 | 2022-03-03 | ||
WO2023054477A1 (ja) * | 2021-09-28 | 2023-04-06 | 森永乳業株式会社 | アロエ抽出物の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2602066C (en) | 2014-02-11 |
EP1952817A1 (en) | 2008-08-06 |
JP4095115B2 (ja) | 2008-06-04 |
US20130079314A1 (en) | 2013-03-28 |
KR100897492B1 (ko) | 2009-05-15 |
CN103494998A (zh) | 2014-01-08 |
EP1952817B1 (en) | 2013-05-22 |
AU2006317258B2 (en) | 2008-12-18 |
US8709512B2 (en) | 2014-04-29 |
CN101128211B (zh) | 2014-08-13 |
US20110104314A1 (en) | 2011-05-05 |
US20090004307A1 (en) | 2009-01-01 |
ES2576845T3 (es) | 2016-07-11 |
EP2206509B1 (en) | 2016-03-23 |
RU2356572C1 (ru) | 2009-05-27 |
AU2006317258A1 (en) | 2007-05-31 |
JPWO2007060911A1 (ja) | 2009-05-07 |
EP1952817A4 (en) | 2009-09-23 |
KR20070096010A (ko) | 2007-10-01 |
ES2425149T3 (es) | 2013-10-11 |
CN101128211A (zh) | 2008-02-20 |
CN103494998B (zh) | 2015-08-12 |
EP2206509A1 (en) | 2010-07-14 |
CA2602066A1 (en) | 2007-05-31 |
US8877265B2 (en) | 2014-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007060911A1 (ja) | アロエベラ抽出物、アロエベラ抽出物の製造方法、高血糖改善剤 | |
JP4590491B2 (ja) | 過酸化脂質生成抑制のための医薬 | |
KR101148901B1 (ko) | 고혈당 개선용 음식품 | |
JP6285049B2 (ja) | 性ホルモンのバランスの乱れに起因する症状の予防又は改善剤 | |
WO2006123466A1 (ja) | 膵臓機能改善のための医薬又は飲食品 | |
WO2007043294A9 (ja) | 内臓脂肪蓄積抑制剤 | |
JP4611775B2 (ja) | 血圧降下剤 | |
RU2481116C2 (ru) | Антиоксидант | |
WO2019043998A1 (ja) | 深部体温上昇用組成物 | |
JP2019043863A (ja) | Ucp発現促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 11815428 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007546430 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077018270 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006823482 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006317258 Country of ref document: AU Ref document number: 3548/CHENP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200680006127.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2006317258 Country of ref document: AU Date of ref document: 20061120 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006317258 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2602066 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007137518 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |